This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2009 Apr 23;113(17):3888-9.

doi: 10.1182/blood-2008-12-191478.

REVelation (del: 5q)

Mikkael A Sekeres¹

Affiliations

PMID: 19389890
DOI: 10.1182/blood-2008-12-191478

Free article

Comment

REVelation (del: 5q)

Mikkael A Sekeres. Blood. 2009.

Free article

. 2009 Apr 23;113(17):3888-9.

doi: 10.1182/blood-2008-12-191478.

Author

Mikkael A Sekeres¹

Affiliation

¹ Cleveland Clinic, Taussig Cancer Institute, Cleveland, Ohio, USA.

PMID: 19389890
DOI: 10.1182/blood-2008-12-191478

No abstract available

PubMed Disclaimer

Comment on

Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study.
Adès L, Boehrer S, Prebet T, Beyne-Rauzy O, Legros L, Ravoet C, Dreyfus F, Stamatoullas A, Chaury MP, Delaunay J, Laurent G, Vey N, Burcheri S, Mbida RM, Hoarau N, Gardin C, Fenaux P. Adès L, et al. Blood. 2009 Apr 23;113(17):3947-52. doi: 10.1182/blood-2008-08-175778. Epub 2008 Nov 5. Blood. 2009. PMID: 18987358 Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Silverchair Information Systems